Marnetegragene Autotemcel

Brand names: Kresladi · Active ingredient: Marnetegragene Autotemcel

In short: KRESLADI is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant. This indication is approved

Forms & strengthsKRESLADI is a cell suspension for intravenous infusion. KRESLADI is composed of one or two infusion bags which contain 0.34 to 6.1 × 106 cells/mL (including 0.32 to 6.1 × 106 CD34+ cells/mL) suspended in a cryopreservation solution . …
LabelRocket Pharmaceuticals, Inc.
Label updatedJul 06, 2026

What is Marnetegragene Autotemcel used for?

KRESLADI is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.

This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Marnetegragene Autotemcel dosage

For autologous use only. For one-time single-dose intravenous use only.

The recommended minimum dose of KRESLADI is a single intravenous infusion of 2.8 × 106 CD34+ cells/kg.

The dose is calculated based on the patient's weight prior to first apheresis.

See the Lot Information Sheet provided with the product shipment for additional information pertaining to dose. Up to two drug product lots may be administered to meet the minimum dose.

Before mobilization, apheresis, and conditioning are initiated, confirm that autologous hematopoietic stem cell (HSC) transplantation is appropriate for the patient.

Consider administering ustekinumab prior to mobilization and apheresis and/or prior to KRESLADI infusion.

Mobilization and Apheresis

Administer granulocyte-colony-stimulating factor (G-CSF) and plerixafor for HSC mobilization followed by apheresis to obtain CD34+ cells for product manufacturing.

Weigh the patient prior to the first apheresis collection. Collect a recommended target number of CD34+ cells of 20 × 106 CD34+ cells/kg.

Repeat additional cycles of mobilization and apheresis after at least 14 days to obtain more cells for KRESLADI manufacture if the minimum dose of 2.8 × 106 CD34+ cells/kg is not met.

Back-Up CD34+ Cell Collection

Obtain and cryopreserve an additional collection of CD34+ cells of ≥ 2 × 106 CD34+ cells/kg at the treatment center prior to initiating myeloablative conditioning and infusion with KRESLADI. Administer the back-up collection for rescue treatment if there is: 1) compromise of KRESLADI after initiation of conditioning and before KRESLADI infusion, 2) primary engraftment failure, or 3) loss of engraftment after infusion with KRESLADI.

Myeloablative Conditioning

Do not begin conditioning until KRESLADI has been received and stored at the treatment center and the availability of the back-up collection of CD34+ cells is confirmed.

Administer myeloablative conditioning before infusion of KRESLADI based on institutional guidelines. Consult the prescribing information for the conditioning agents prior to treatment.

Infuse KRESLADI 24-48 hours after completion of myeloablative conditioning.

Receipt and Storage of KRESLADI

Ensure the availability of vapor phase of liquid nitrogen storage at less than or equal to -150°C (-238°F) at the treatment center.

KRESLADI is shipped to the treatment center in the vapor phase of liquid nitrogen shipper.

Confirm the patient's identity with the patient identifiers on the shipper and labels.

If there are any concerns about the product or packaging upon receipt, contact Rocket Pharmaceuticals at 1-800-982-2410. …

How to take Marnetegragene Autotemcel — instructions & advice from the label

Manufacturing Failure

Ensure that the patient and/or caregiver understand the risk of manufacturing failure. In case of manufacturing failure or the need for additional cells, additional cell collection and manufacturing of KRESLADI would be needed .

Serious Infections

Inform the patient and/or caregiver that patients are at increased risk of developing a variety of infections, which may be due to administration of myeloablative conditioning prior to treatment with KRESLADI. Advise the patient and/or caregiver to contact their healthcare provider if the patient develops any symptoms of infection such as fever, sweats or chills, cough or flu-like symptoms, muscle aches, or warm, red, painful areas on the skin .

Veno-Occlusive Disease

Inform the patient and/or caregiver of the risk of veno-occlusive disease, which may be due to administration of myeloablative conditioning prior to treatment with KRESLADI. Advise the patient and/or caregiver of the plan to monitor liver function following treatment with KRESLADI . …

Warnings & precautions

Do not take this medicine if: None.

Serious infections have occurred with KRESLADI administration . Increased susceptibility to infections may occur due to administration of myeloablative conditioning prior to KRESLADI infusion.

Monitor patients for signs and symptoms of infection before and after KRESLADI infusion and treat appropriately. Administer prophylactic antimicrobials according to institutional guidelines.

Avoid administration of KRESLADI in patients with active bloodstream infections or other serious, untreated infections.

Any blood products required after KRESLADI infusion should be irradiated.

Veno-occlusive disease has occurred with KRESLADI treatment . Increased susceptibility to veno-occlusive disease may occur due to administration of myeloablative conditioning prior to KRESLADI infusion. Monitor patients for signs and symptoms of veno-occlusive disease including assessment of liver function tests during the first month following KRESLADI infusion.

Neutrophil engraftment failure may occur after treatment with KRESLADI. Neutrophil engraftment failure is defined as failure to achieve three consecutive absolute neutrophil counts (ANC) ≥ 500 cells/microliter obtained on different days by Day 43 after infusion of KRESLADI. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a patient treated with KRESLADI, provide rescue treatment with the back-up collection of CD34+ cells .

Delayed platelet engraftment may occur after treatment with KRESLADI. Monitor platelet counts and bleeding until platelet engraftment and platelet recovery are achieved.

Lentiviral vector (LVV)-mediated insertional oncogenesis may occur after treatment with KRESLADI. Hematologic malignancy is a lifelong risk and patients treated with KRESLADI may develop hematologic malignancy at any time following treatment. …

Marnetegragene Autotemcel side effects

As clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in this section reflect exposure to KRESLADI in one clinical study (Study RP-L201-0318). A total of 9 pediatric patients with severe LAD-I received a single dose of intravenous KRESLADI with a median dose of 4.3 × 106 CD34+ cells/kg (range: 2.8 to 10 CD34+ cells/kg) . The median duration of follow up after KRESLADI administration was 4.2 years (range: 3.6 to 5.7 years).

Serious adverse reactions were reported in 4 patients (44%) including serious infections (n=4), pulmonary arterial hypertension (n=1), sensorineural deafness (n=1), and veno-occlusive disease (n=1).

Table 1 presents the most common adverse reactions reported in Study RP-L201-0318.

Adverse Reaction | All Grades (%) | Grade ≥3 (%)

Gastrointestinal disorders

Note: Adverse reactions are defined as adverse events that occurred from myeloablative conditioning administration through year 2 following KRESLADI administration. …

Drug interactions

No formal drug interaction studies have been performed. KRESLADI is not expected to interact with the hepatic cytochrome P-450 family of enzymes or drug transporters.

The safety and effectiveness of immunization with live viral vaccines during or following KRESLADI treatment has not been studied. Vaccination is not recommended during the 6 weeks preceding the start of myeloablative conditioning, and until hematological recovery following treatment with KRESLADI. Where feasible, administer childhood vaccinations prior to myeloablative conditioning for KRESLADI.

Patients should not take anti-retroviral medications for at least one month prior to initiating medications for stem cell mobilization and for the expected duration for elimination of the medications, and until all cycles of apheresis are completed . Anti-retroviral medications may interfere with manufacturing of KRESLADI.

About this medicine

KRESLADI (marnetegragene autotemcel) is an autologous hematopoietic stem cell (HSC)-based gene therapy prepared from the patient's HSCs, which are collected via apheresis procedure(s). The autologous cells are enriched for CD34+ cells, then transduced ex vivo with LV-RP-201 overnight in the presence of defined growth factors before harvest and suspended in a cryopreservation solution. LV-RP-201 is a replication-incompetent, self-inactivating lentivirus vector encoding for the CD18 β-subunit of human β2 integrins (ITGB2). The ITGB2 gene is under the control of a human chimeric promoter (a fusion of the FES and CTSG minimal 5'-flanking regions).

The transduced CD34+ cells are washed, formulated into a suspension, and then cryopreserved. KRESLADI is frozen in a patient-specific infusion bag(s) and is thawed prior to intravenous administration . The thawed product is a colorless to slightly white suspension of cells. Due to the presence of cells, the solution may be clear to slightly cloudy and may contain visible cell aggregates. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 97db9c3c-20c2-4dad-890c-bc821805421f. Read the full official label on DailyMed.